PUBLIC COMPANY
save$CRBUCaribou Biosciences, Inc.
$CRBUBerkeley, CA, USupdated 3mo ago
Rachel Elizabeth Haurwitz is an American biochemist and structural biologist. She is the co-founder, chief executive officer, and president of Caribou Biosciences, a genome editing company.
community read0 votes
pipeline
2
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(2)
pipeline depth2 products
2Phase 1
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- —Long-Term Follow-up Study
- phase1CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
- phase1CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients With Refractory Systemic Lupus Erythematosus (GALLOP)
- phase1CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- phase1CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
🐶 Hiring Signal
Where Caribou Biosciences, Inc. is staffing up — a leading indicator of pipeline and commercial priorities.
therapeutic areaOncology 1
News
- Biopharma layoffs rise YOY in October but sharply trend down for 2026October marked the first time this year there was an increase in both the number of biotech and pharma companies trimming their workforces and the number of affected employees when compared to 2025…biospace · 5d ago
- In the hunt for reverse merger targets, Caribou could be prized gameThe struggling cell therapy developer is exploring strategic alternatives, which, among other characteristics, make it a likely candidate to receive reverse merger interest.biopharma_dive · 1mo ago
- STAT+: Biotech companies are struggling to navigate Trump’s new tariffsSmaller biotech firms are trying to figure out how to win exemptions from Trump's import taxes.stat · 1mo ago
- A mother-daughter quest to find fellow members of an ultra-rare genetic community“Don’t google,” the pediatric geneticist warned. It took me five years to disobey.stat · 1mo ago
- STAT+: PhRMA sues over Trump policy mandating lower drug prices in MedicareThe brand drug industry’s main trade group is suing the Trump administration over a pilot program tying Medicare drug prices to those in peer countries.stat · 1mo ago
- Caribou to halt CAR-T work, lay off staff amid ‘challenging’ funding climateDespite having an allogeneic cell therapy prospect that’s ready for late-stage testing in lymphoma, Caribou couldn’t secure funding to support the effort and will now pursue “strategic alternatives…biopharma_dive · 1mo ago
- STAT+: Forbion raises $2.6 billion, its largest fundraise to dateForbion, a prominent European venture capital firm, said it has raised $2.6 billion, its largest fundraise to date and one of the largest in the region in recent years.stat · 1mo ago
- Cadrenal launches strategic review for late-stage cardiology pipelineCadrenal Therapeutics, a heart-focused biotech that recently reached an agreement with the FDA on the design of a pivotal trial for its lead candidate, is now instead looking to offload its pipelin…fiercebiotech · 1mo ago
- Doudna’s CAR T biotech Caribou to end R&D activities, slash staff as financing freezes upCaribou Biosciences entered the scene in 2011 and went public in 2021. Over the course of its existence, the biotech has received funding and support from a handful of Big Pharma players, including…biospace · 1mo ago
- STAT+: In Duchenne muscular dystrophy, a promising therapy is available to a fortunate fewExon-skipping drugs present a critical test for the FDA’s goal of encouraging treatments for rare disease.stat · 1mo ago
Data sources
last refreshed 18m ago
Found something off?
comments(0)
5-min edit window · permanent after that